BACKGROUND: The TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mouse model has frequently been used in preclinical studies with chemotherapeutic/chemopreventive rationales. Here the hypothesis was tested using (1)H-NMR-based metabolic profiling that the TRAMP tumor metabolic phenotype resembles that reported for human prostate cancer. METHODS: Aqueous extracts or intact tissues of normal prostate from 8- ("young") or 28-("old") week-old C57BL/6J wild-type mice or of prostate tumor from age-matched TRAMP mice were analyzed by (1)H-NMR. Results were compared with immunohistochemical findings. Expression of choline kinase was studied at the protein and mRNA levels. RESULTS: In young TRAMP mice presenting with zonal hyperplasia, the ratio of glycerophosphocholine (GPC) to phosphocholine (PC) was 22% below that in wild-type mice (P < 0.05). In old TRAMP mice with well-defined malignancy, reduced tumor levels of citrate (49%), choline (33%), PC (57%), GPC (66%), and glycerophosphoinositol (61%) were observed relative to normal prostate (P < 0.05). Hierarchical cluster analysis of metabolite levels distinguished between normal and malignant tissue in old but not young mice. While the reduction in tissue citrate resembles human prostate cancer, low levels of choline species in TRAMP tumors suggest atypical phospholipid metabolism as compared to human prostate cancer. TRAMP tumor and normal prostate tissues did not differ in expression of choline kinase, which is overexpressed in human prostate cancer. CONCLUSION: Although prostate cancer in TRAMP mice shares some metabolic features with that in humans, it differs with respect to choline phospholipid metabolism, which could impact upon the interpretation of results from biomarker or chemotherapy/chemoprevention studies. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: The TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mouse model has frequently been used in preclinical studies with chemotherapeutic/chemopreventive rationales. Here the hypothesis was tested using (1)H-NMR-based metabolic profiling that the TRAMPtumor metabolic phenotype resembles that reported for humanprostate cancer. METHODS: Aqueous extracts or intact tissues of normal prostate from 8- ("young") or 28-("old") week-old C57BL/6J wild-type mice or of prostate tumor from age-matched TRAMPmice were analyzed by (1)H-NMR. Results were compared with immunohistochemical findings. Expression of choline kinase was studied at the protein and mRNA levels. RESULTS: In young TRAMPmice presenting with zonal hyperplasia, the ratio of glycerophosphocholine (GPC) to phosphocholine (PC) was 22% below that in wild-type mice (P < 0.05). In old TRAMPmice with well-defined malignancy, reduced tumor levels of citrate (49%), choline (33%), PC (57%), GPC (66%), and glycerophosphoinositol (61%) were observed relative to normal prostate (P < 0.05). Hierarchical cluster analysis of metabolite levels distinguished between normal and malignant tissue in old but not young mice. While the reduction in tissue citrate resembles humanprostate cancer, low levels of choline species in TRAMPtumors suggest atypical phospholipid metabolism as compared to humanprostate cancer. TRAMPtumor and normal prostate tissues did not differ in expression of choline kinase, which is overexpressed in humanprostate cancer. CONCLUSION: Although prostate cancer in TRAMPmice shares some metabolic features with that in humans, it differs with respect to cholinephospholipid metabolism, which could impact upon the interpretation of results from biomarker or chemotherapy/chemoprevention studies. (c) 2008 Wiley-Liss, Inc.
Authors: Olaf Beckonert; Muireann Coen; Hector C Keun; Yulan Wang; Timothy M D Ebbels; Elaine Holmes; John C Lindon; Jeremy K Nicholson Journal: Nat Protoc Date: 2010-05-13 Impact factor: 13.491
Authors: Xinchun Zhou; Thomas J Lawrence; Zhi He; Charles R Pound; Jinghe Mao; Steven A Bigler Journal: Exp Mol Pathol Date: 2011-11-11 Impact factor: 3.362
Authors: David Gallego-Ortega; Ana Ramirez de Molina; Maria Angeles Ramos; Fatima Valdes-Mora; Maria Gonzalez Barderas; Jacinto Sarmentero-Estrada; Juan Carlos Lacal Journal: PLoS One Date: 2009-11-12 Impact factor: 3.240
Authors: Xinchun Zhou; Jinghe Mao; Junmei Ai; Youping Deng; Mary R Roth; Charles Pound; Jeffrey Henegar; Ruth Welti; Steven A Bigler Journal: PLoS One Date: 2012-11-12 Impact factor: 3.240